CriticalSelective irreversible monoamine oxidase B inhibitor×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Rasagiline is a potent, irreversible, selective inhibitor of monoamine oxidase type B (MAO-B) (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA). Tranylcypromine irreversibly and non-selectively inhibits MAO A and B (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Together with other MAO inhibitors, rasagiline may lead to non-selective MAO inhibition, which may cause a hypertensive crisis (rasagiline SmPC, EMA). The selectivity of rasagiline for MAO-B falls as the dose rises (rasagiline label, US Food and Drug Administration, FDA), and a rasagiline overdose may cause marked inhibition of both MAO-A and MAO-B (rasagiline SmPC, EMA). Full MAO activity returns 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine FDA label).
Symptoms
The main risk of the combination is a hypertensive crisis (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA; rasagiline and tranylcypromine labels, US Food and Drug Administration, FDA). According to the Spanish tranylcypromine SmPC, other monoamine oxidase (MAO) inhibitors also carry a risk of symptoms similar to serotonin syndrome (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US rasagiline label gives the risk of serotonin syndrome as another reason to contraindicate other MAO inhibitors. Serotonin syndrome presents with confusion, hallucinations, agitation, high fever, sweating, fast heart rate, muscle rigidity, myoclonus and overactive reflexes, and it can be fatal (rasagiline FDA label). A hypertensive crisis with tranylcypromine may come with a fast heart rate, facial flushing, headache (especially at the back of the head), neck stiffness, nausea, vomiting and sensitivity to light. In isolated cases, particularly with a drug interaction, it may lead to intracranial haemorrhage (tranylcypromine SmPC, AEMPS). In a hypertensive emergency, blood pressure is severely raised (for example, above 180/120 mm Hg), there are signs of organ damage, and sweating, dilated pupils, shortness of breath, confusion, constricting chest pain and seizures may occur (tranylcypromine FDA label).
Management
The combination is contraindicated. The rasagiline summary of product characteristics (SmPC) lists treatment with other monoamine oxidase (MAO) inhibitors among its contraindications (rasagiline SmPC, European Medicines Agency, EMA), and the Spanish tranylcypromine SmPC contraindicates other MAO inhibitors (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US rasagiline label contraindicates any MAO inhibitor, selective or non-selective, and gives tranylcypromine as an example of a non-selective one. The US tranylcypromine label lists rasagiline by name among contraindicated drugs (rasagiline and tranylcypromine labels, US Food and Drug Administration, FDA). Start tranylcypromine no earlier than 14 days after stopping rasagiline (rasagiline SmPC, EMA; rasagiline FDA label). After stopping tranylcypromine, the Spanish SmPC recommends waiting 14 days before starting a drug that is incompatible with it (tranylcypromine SmPC, AEMPS). Measure blood pressure before starting tranylcypromine and monitor it closely during treatment (tranylcypromine FDA label). During rasagiline treatment, watch for new hypertension or worsening control of existing hypertension (rasagiline FDA label). If the drugs have nevertheless been taken together and palpitations, headache or other early signs of a hypertensive crisis appear, interrupt treatment and assess the patient at once. Immediately stop tranylcypromine and any other drug that may have caused the crisis. If blood pressure is above 180/120 mm Hg with signs of organ damage, lower it immediately (tranylcypromine FDA label). If serotonin syndrome develops, stop tranylcypromine and all serotonergic drugs at once and start supportive symptomatic treatment (tranylcypromine FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.3 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, información del producto actualizada 08/04/2025, secciones 4.3, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1